Before you sell to, join or invest in Antares Therapeutics, Inc.
MentionFox check on Antares Therapeutics, Inc.: only 1 source on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/antares-therapeutics-inc-form-d-25000002
Check Antares Therapeutics, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Antares Therapeutics, Inc.?
Based on the record MentionFox holds for this company. No flag is not a clearance.
Antares Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-03-12.
Antares Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on March 12, 2025. The filing reports $40M sold. Its industry group is Biotechnology. It names Adam Friedman (Executive Officer, Director), Brian Piper (Executive Officer, Director), Andrew Fedder (Executive Officer, Director) (SEC Form D, March 12, 2025).
Is this your company?
Sell to companies like Antares Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-03-12 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Antares Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Antares Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed within 90 days of this one, largest first.
Get an email when Antares Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Antares Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Antares Therapeutics, Inc. →Get the full cited report on Antares Therapeutics, Inc.
What the filing shows about Antares Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Antares Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Antares Therapeutics, Inc.'s address as One Winthrop Square, Suite 400, Boston, MA 02110.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Antares Therapeutics, Inc. See pricing
Antares Therapeutics, Inc. is a registered filer with the SEC (CIK 2059043) and has filed since 2025-03-12. 2 filings are on record, the latest on 2025-05-15.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Antares Therapeutics, Inc.'s Form D of 2025-03-12 names Adam Friedman, Brian Piper and Andrew Fedder as its officers, directors or promoters.
Its new offerings report $70M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Adam Friedman is named as Executive Officer and Director on the Form D that Antares Therapeutics, Inc. filed with the SEC on 12 March 2025, one of 3 people that filing names.
Brian Piper is named as Executive Officer and Director on the Form D that Antares Therapeutics, Inc. filed with the SEC on 12 March 2025, one of 3 people that filing names.
Andrew Fedder is named as Executive Officer and Director on the Form D that Antares Therapeutics, Inc. filed with the SEC on 12 March 2025, one of 3 people that filing names.
3 people named on the filing — 3 holding an executive role.
Named as of the 2025-03-12 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Antares Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Antares Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Antares Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Antares Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Antares Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Antares Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/antares-therapeutics-inc-form-d-25000002